CH5183284 (Debio-1347) is a selective inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinase, with high specificity for FGFR1, FGFR2, and FGFR3. It is primarily investigated for its potential in cancer therapy, particularly in tumors driven by FGFR genetic alterations such as gene amplifications, fusions, or mutations. The compound has shown preclinical efficacy in models of various solid tumors, including gastric, lung, and bladder cancers, where FGFR signaling plays a key role in tumor growth and survival. Due to its selectivity, CH5183284 aims to minimize off-target effects commonly seen with broader kinase inhibitors, potentially improving safety and tolerability. It has been evaluated in early-phase clinical trials to assess its pharmacokinetics, optimal dosing, and anti-tumor activity in patients with advanced malignancies harboring FGFR pathway abnormalities. Its development supports the growing field of precision oncology, where treatments are tailored based on the molecular profile of a patient’s tumor.